CPC A61K 9/0046 (2013.01) [A61K 9/0048 (2013.01); A61K 33/14 (2013.01); A61K 33/18 (2013.01); A61K 33/20 (2013.01); A61K 33/40 (2013.01); A61K 45/06 (2013.01); A61K 51/00 (2013.01); A61K 9/00 (2013.01); A61K 9/0012 (2013.01); A61K 9/0043 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01)] | 7 Claims |
1. A method for reducing formation of fibrosis in at least one nasolacrimal duct of a patient that may occur upon the patient receiving radioactive iodine, the method comprising administering to the patient by topically delivering an ophthalmic composition comprising perchlorate anion to at least one eye of the patient, or instilling the ophthalmic composition directly into the at least one nasolacrimal duct or at least one lacrimal sac of the patient, wherein the perchlorate anion is at a concentration of about 40 mg/ml to about 400 mg/ml and the ophthalmic composition further comprises at least one of white petrolatum, mineral oil, lanolin, or polyethylene mineral oil gel.
|